Details of the Drug Combination

General Information of Drug Combination (ID: DCWDG2S)

Drug Combination Name
SY-1425 Terameprocol
Indication
Disease Entry Status REF
Glioma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Terameprocol   DMC3P45
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SF-295
Zero Interaction Potency (ZIP) Score: 1.67
Bliss Independence Score: 4.2
Loewe Additivity Score: 3.17
LHighest Single Agent (HSA) Score: 1.19

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DCUU5KG SNB-19 Investigative [1]
Childhood T acute lymphoblastic leukemia DCUQWIC CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DCHTK01 K-562 Investigative [1]
Papillary renal cell carcinoma DC3O9QK ACHN Investigative [1]
Renal cell carcinoma DCI4FN3 UO-31 Investigative [1]
Invasive ductal carcinoma DCKS5JY T-47D Investigative [4]
Adenocarcinoma DCSN8T0 NCIH23 Investigative [5]
Adenocarcinoma DCE49JO HCT116 Investigative [5]
Adenocarcinoma DCAYAR2 HCT-15 Investigative [5]
Adenocarcinoma DC9OIZJ SW-620 Investigative [5]
Cutaneous melanoma DCK9XX9 SK-MEL-28 Investigative [5]
Large cell lung carcinoma DCSFEFK NCI-H460 Investigative [5]
Mixed endometrioid and clear cell carcinoma DC9AKQ7 IGROV1 Investigative [5]
Non-small cell lung carcinoma DCTGDSH HOP-92 Investigative [5]
Prostate carcinoma DCN4GSL PC-3 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976